The Chronic Kidney Disease Model: A General Purpose Model of Disease Progression and Treatment.

dc.contributor.authorOrlando, L. A.
dc.contributor.authorBelasco, Eric J.
dc.contributor.authorPatel, U. D.
dc.contributor.authorMatcher, D. B.
dc.date.accessioned2015-02-12T22:22:49Z
dc.date.available2015-02-12T22:22:49Z
dc.date.issued2011-06
dc.description.abstractBackground: Chronic kidney disease (CKD) is the focus of recent national policy efforts; however, decision makers must account for multiple therapeutic options, comorbidities and complications. The objective of the Chronic Kidney Disease model is to provide guidance to decision makers. We describe this model and give an example of how it can inform clinical and policy decisions. Methods: Monte Carlo simulation of CKD natural history and treatment. Health states include myocardial infarction, stroke with and without disability, congestive heart failure, CKD stages 1-5, bone disease, dialysis, transplant and death. Each cycle is 1 month. Projections account for race, age, gender, diabetes, proteinuria, hypertension, cardiac disease, and CKD stage. Treatment strategies include hypertension control, diabetes control, use of HMG-CoA reductase inhibitors, use of angiotensin converting enzyme inhibitors, nephrology specialty care, CKD screening, and a combination of these. The model architecture is flexible permitting updates as new data become available. The primary outcome is quality adjusted life years (QALYs). Secondary outcomes include health state events and CKD progression rate. Results: The model was validated for GFR change/year -3.0 ± 1.9 vs. -1.7 ± 3.4 (in the AASK trial), and annual myocardial infarction and mortality rates 3.6 ± 0.9% and 1.6 ± 0.5% vs. 4.4% and 1.6% in the Go study. To illustrate the model's utility we estimated lifetime impact of a hypothetical treatment for primary prevention of vascular disease. As vascular risk declined, QALY improved but risk of dialysis increased. At baseline, 20% and 60% reduction: QALYs = 17.6, 18.2, and 19.0 and dialysis = 7.7%, 8.1%, and 10.4%, respectively. Conclusions: The CKD Model is a valid, general purpose model intended as a resource to inform clinical and policy decisions improving CKD care. Its value as a tool is illustrated in our example which projects a relationship between decreasing cardiac disease and increasing ESRD.en_US
dc.identifier.citationOrlando, L.A., E.J. Belasco, U.D. Patel, and D.B. Matcher. "The Chronic Kidney Disease Model: A General Purpose Model of Disease Progression and Treatment." BMC Medical Informatics and Decision Making. Vol 11, No. 41 (2011).en_US
dc.identifier.issn1472-6947
dc.identifier.urihttps://scholarworks.montana.edu/handle/1/8843
dc.subjectEconomicsen_US
dc.subjectHealth sciencesen_US
dc.subjectEpidemiologyen_US
dc.titleThe Chronic Kidney Disease Model: A General Purpose Model of Disease Progression and Treatment.en_US
dc.typeArticleen_US
mus.citation.issue41en_US
mus.citation.journaltitleBMC Medical Informatics and Decision Makingen_US
mus.citation.volume11en_US
mus.identifier.categoryBusiness, Economics & Managementen_US
mus.identifier.categoryHealth & Medical Sciencesen_US
mus.identifier.doi10.1186/1472-6947-11-41en_US
mus.relation.collegeCollege of Letters & Science
mus.relation.collegeCollege of Letters & Scienceen_US
mus.relation.departmentAgricultural Economics & Economics.en_US
mus.relation.universityMontana State University - Bozemanen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Belasco_BMCMedicalInformaticsAndDecisionMaking_06_2011.pdf
Size:
322.39 KB
Format:
Adobe Portable Document Format
Description:
The Chronic Kidney Disease Model: A General Purpose Model of Disease Progression and Treatment (PDF)

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
826 B
Format:
Item-specific license agreed upon to submission
Description:
Copyright (c) 2002-2022, LYRASIS. All rights reserved.